Gsk GSK
NYSE GSK
$52.34 +0.38 (+0.73%)
As of: Aug 21, 2026 · 11:45 AM EDT

Gsk (GSK) Non-Current Debt (2009 - 2026)

Gsk (GSK) posted quarterly Non-Current Debt of -$18.7 billion for Q2 2026, up 8.35% year-over-year from -$17.3 billion in Q2 2025, and up 0.94% quarter-over-quarter from -$18.9 billion in Q1 2026.

Gsk (GSK) Non-Current Debt (2009 - 2026) Analysis & Trends

Gsk's Non-Current Debt history runs 18 years deep, the most recent figure standing at -$18.7 billion for Q2 2026.

  • In Q2 2026, Non-Current Debt rose 8.35% year-over-year to -$18.7 billion; the TTM figure through Jun 2026 stood at -$18.7 billion (up 8.35% YoY), while the FY2025 annual figure was -$19.4 billion, down 203.91% from the prior year.
  • Non-Current Debt for Q2 2026 stood at -$18.7 billion, up from -$18.9 billion in the prior quarter.
  • The five-year high for Non-Current Debt was $18.9 billion in Q4 2023, with the low at -$23.7 billion in Q2 2022.
  • The 5-year median for Non-Current Debt is -$19.3 billion (2023), against an average of -$13.7 billion.
  • The sharpest annual moves came in 2023 and 2025: Non-Current Debt jumped 178.32% in 2023, then sank 204.4% in 2025.
  • Gsk's Non-Current Debt stood at $6.8 billion in 2022, then surged by 178.32% to $18.9 billion in 2023, then retreated by 0.67% to $18.7 billion in 2024, then tumbled by 204.4% to -$19.6 billion in 2025, then advanced by 4.35% to -$18.7 billion in 2026.
  • Business Quant data shows GSK's Non-Current Debt at -$18.7 billion in Q2 2026, -$18.9 billion in Q1 2026, and -$19.6 billion in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 653.66 Bn 632.90 Bn 17.26 Bn 37.34 Bn
2 AbbVie 469.84 Bn 463.27 Bn 12.70 Bn 62.48 Bn
3 Merck 378.23 Bn 371.09 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 303.01 Bn 295.32 Bn 11.24 Bn -
5 Astrazeneca 258.57 Bn 253.67 Bn 12.86 Bn 23.68 Bn
6 Amgen 237.36 Bn 223.37 Bn 7.24 Bn 57.30 Bn
7 Gilead Sciences 183.27 Bn 180.09 Bn 6.22 Bn 26.25 Bn
8 Pfizer 160.74 Bn 149.04 Bn 10.94 Bn 60.50 Bn
9 Gsk 105.88 Bn 101.72 Bn 8.24 Bn -18.71 Bn
10 Sanofi 55.28 Bn 47.90 Bn 10.79 Bn 17.02 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 -18.71 Bn
Mar 31, 2026 -18.89 Bn
Dec 31, 2025 -19.56 Bn
Sep 30, 2025 -20.10 Bn
Jun 30, 2025 -20.42 Bn
Mar 31, 2025 -20.75 Bn
Dec 31, 2024 18.74 Bn
Sep 30, 2024 -17.21 Bn
Jun 30, 2024 -17.14 Bn
Mar 31, 2024 -19.23 Bn
Dec 31, 2023 18.87 Bn
Sep 30, 2023 -20.26 Bn
Jun 30, 2023 -19.46 Bn
Mar 31, 2023 -20.23 Bn
Dec 31, 2022 6.78 Bn
Sep 30, 2022 -22.77 Bn
Jun 30, 2022 -23.65 Bn
Mar 31, 2022 -12.56 Bn
Dec 31, 2021 6.90 Bn
Sep 30, 2021 -28.59 Bn